ORLANDO, Fla., Feb. 20, 2017 -- (HIMSS Booth #6045) -- 2bPrecise, LLC today announced the general availability of its EHR-agnostic, cloud-based precision medicine platform. The 2bPrecise solution captures and securely stores genomic data, which it harmonizes with research knowledge and clinical information. It then pushes the resulting insights to the point of care, enabling the clinician to take action.
|
|||
2bPrecise is now giving physicians across the country the ability to practically apply precision medicine to diagnose and treat their patients. National Institutes of Health and Holston Medical Group are currently participating in early adopter programs. By delivering understandable and actionable genomic insights into physicians’ existing clinical workflows, the platform enables informed decision-making in an effort to improve outcomes and reduce costs.
“As the pace of genomic discovery continues to accelerate, the mountain of genetic data – separated in clinical, lab or other systems – continues to grow,” said Assaf Halevy, founder and CEO of 2bPrecise. “For patients to benefit from this expanding body of knowledge, we need to get the relevant insights into the hands of treating providers without disrupting their existing workflows. 2bPrecise is the last-mile solution that closes this information gap, empowering physicians to provide the most precise care.”
A wholly owned subsidiary of Allscripts Healthcare Inc., 2bPrecise’s vendor-neutral solution is uniquely positioned for success. “Allscripts prides itself on its reputation for investing in open platforms driven by entrepreneurial leaders, with the goal of helping providers regardless of their current HCIT platform,” said Paul Black, CEO of Allscripts. “Our support of 2bPrecise is no exception, and we are committed to helping cultivate its innovative approach to precision medicine; making genomic insights actionable and accessible for providers.”
Key components of the 2bPrecise platform include:
- A genomic repository that semantically tags information from a range of clinical and genomic sources, and that extracts meaningful insights for providers and researchers.
- A robust knowledge hub that assembles information from a wide range of sources, enabling providers to access the most current clinically validated information available.
- A point of care solution that delivers actionable genomic intelligence directly into the existing workflow.
- A research-ready framework for closed-loop research-to-care translations that can establish the foundation for future scientific discovery.
To learn more, visit 2bPrecise at HIMSS booth #6045.
About 2bPrecise
2bPrecise harnesses the power of genomics and precision medicine in an effort to precisely predict and efficiently treat each individual patient. 2bPrecise’s EHR-agnostic, cloud-based platform captures and stores genomic data and harmonizes it with research knowledge and clinical information. The resulting actionable insights are then pushed into a provider’s existing clinical workflow to facilitate decision-making at the point of care. Learn more at www.2bPrecisehealth.com.
About Allscripts
Allscripts (NASDAQ:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
Media Contact: Danielle Johns Aria Marketing for 2bPrecise [email protected] 617-332-9999 x241 Concetta Rasiarmos Allscripts Public Relations [email protected] 630-740-3152 Investors: Seth Frank Allscripts Vice President of Investor Relations 312-506-1213 [email protected]


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Instagram Outage Disrupts Thousands of U.S. Users
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



